The National Health Authority (NHA) aims to deliver 10 crore Ayushman Bharat cards in this financial year and extend free hospitalization benefits to 50 lakh people in a quarter
The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
It has been built at a cost of Rs 19.5 crores through internal accruals of the Malabar Institute of Medical Sciences (MIMS)
Incorporating multi-modality image guidance, Ethos therapy provides the ability to personalize the patient's treatment based on their anatomy and position at the time of treatment
This clinical study demonstrated that the 14-day regimen of ImmunoSEB and ProbioSEB CSC3 resolved post-Covid-19 fatigue symptoms and improved patients' functional status and quality of life
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
The platform revolutionizes how providers deliver financial services by radically simplifying the patient financial experience
Over 70 per cent of the world’s population have no access to MRI scanners and the situation is not that encouraging in India where there are only 0.4 MRI scanners per thousand people
The medicine is now approved for eight indications across five different types of cancer in China.
Subscribe To Our Newsletter & Stay Updated
